
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,600 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 January 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 3MB, 218 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study”, Drug Saf, 2019.
, “Study Design and Cohort Comparability in a Study of Major Cardiovascular Events in New Users of Prucalopride Versus Polyethylene Glycol 3350”, Drug Saf, 2019.
, “Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom”, Respir Med, vol. 152, pp. 37-43, 2019.
, “GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD)”, Pharmacoepidemiol Drug Saf, 2018.
, “Methodological challenges when evaluating potential off-label prescribing of drugs using electronic health care databases: A case study of dabigatran etexilate in Europe”, Pharmacoepidemiol Drug Saf, vol. 27, pp. 713-723, 2018.
, “Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom”, Epidemiology, vol. 29, pp. 308-313, 2018.
, “Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom”, Epidemiology, vol. 29, pp. e41-e42, 2018.
, “Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias”, Pharmacotherapy, vol. 37, pp. 673-683, 2017.
, “A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction”, Eur J Clin Pharmacol, vol. 72, pp. 1105-16, 2016.
,